Skip to main navigation Skip to search Skip to main content

Health outcomes among HIV-positive Latinos initiating antiretroviral therapy in North America versus Central and South America

  • Carina Cesar
  • , John R. Koethe
  • , Mark J. Giganti
  • , Peter Rebeiro
  • , Keri N. Althoff
  • , Sonia Napravnik
  • , Angel Mayor
  • , Beatriz Grinsztejn
  • , Marcelo Wolff
  • , Denis Padgett
  • , Juan Sierra-Madero
  • , Eduardo Gotuzzo
  • , Timothy R. Sterling
  • , James Willig
  • , Julie Levison
  • , Mari Kitahata
  • , Maria C. Rodriguez-Barradas
  • , Richard D. Moore
  • , Catherine McGowan
  • , Bryan E. Shepherd
  • Pedro Cahn
  • Fundación Huesped
  • Vanderbilt University School of Medicine
  • Johns Hopkins Bloomberg School of Public Health
  • The University of North Carolina at Chapel Hill
  • Universidad Central del Caribe
  • Instituto Nacional de Infectologia Evandro Chagas (INI)
  • Fundación Arriaran–Facultad de Medicina Universidad de Chile
  • Hospital Escuela Universitario
  • Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”
  • University of Alabama at Birmingham
  • Massachusetts General Hospital
  • University of Washington
  • Baylor College of Medicine
  • Johns Hopkins University School of Medicine

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Introduction: Latinos living with HIV in the Americas share a common ethnic and cultural heritage. In North America, Latinos have a relatively high rate of new HIV infections but lower rates of engagement at all stages of the care continuum, whereas in Latin America antiretroviral therapy (ART) services continue to expand to meet treatment needs. In this analysis, we compare HIV treatment outcomes between Latinos receiving ART in North America versus Latin America. Methods: HIV-positive adults initiating ART at Caribbean, Central and South America Network for HIV (CCASAnet) sites were compared to Latino patients (based on country of origin or ethnic identity) starting treatment at North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) sites in the United States and Canada between 2000 and 2011. Cox proportional hazards models compared mortality, treatment interruption, antiretroviral regimen change, virologic failure and loss to follow-up between cohorts. Results: The study included 8400 CCASAnet and 2786 NA-ACCORD patients initiating ART. CCASAnet patients were younger (median 35 vs. 37 years), more likely to be female (27% vs. 20%) and had lower nadir CD4 count (median 148 vs. 195 cells/μL, p<0.001 for all). In multivariable analyses, CCASAnet patients had a higher risk of mortality after ART initiation (adjusted hazard ratio (AHR) 1.61; 95% confidence interval (CI):1.32 to 1.96), particularly during the first year, but a lower hazard of treatment interruption (AHR: 0.46; 95% CI: 0.42 to 0.50), change to second-line ART (AHR: 0.56; 95% CI: 0.51 to 0.62) and virologic failure (AHR: 0.52; 95% CI: 0.48 to 0.57). Conclusions: HIV-positive Latinos initiating ART in Latin America have greater continuity of treatment but are at higher risk of death than Latinos in North America. Factors underlying these differences, such as HIV testing, linkage and access to care, warrant further investigation.

Original languageEnglish
Article number20684
JournalJournal of the International AIDS Society
Volume19
Issue number1
DOIs
StatePublished - 18 Mar 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being
  2. SDG 11 - Sustainable Cities and Communities
    SDG 11 Sustainable Cities and Communities

Keywords

  • Antiretroviral therapy
  • Cohort studies
  • HIV
  • Highly active
  • Latin America
  • Mortality
  • North America

Fingerprint

Dive into the research topics of 'Health outcomes among HIV-positive Latinos initiating antiretroviral therapy in North America versus Central and South America'. Together they form a unique fingerprint.

Cite this